نتائج البحث

FDA-approved disulfiram induces ferroptosis via alteration of redox balance and lipid peroxidation and overcomes carfilzomib resistance in multiple myeloma.

• Authors : Arkan, Caglar¹ (AUTHOR); Akcora-Yildiz, Dilara¹ (AUTHOR)

• Source: Leukemia & Lymphoma. Feb2025, Vol. 66 Issue 2, p250-261. 12p.

تفاصيل العنوان

Combination effects of Pistachio hull and carfilzomib on NF-κB p65, MDR1, MRP1, and Caspase3 gene expression in breast cancer cell line.

• Authors : Mirzaei, Zahra¹ (AUTHOR) ; Zarei, Sadegh² (AUTHOR) ; Sayadi, Ahmadreza³ (AUTHOR)

Subjects: *NF-kappa B; *DATA analysis; *T-test (Statistics)

• Source: BMC Complementary Medicine & Therapies. 1/22/2025, Vol. 25 Issue 1, p1-15. 15p.

تفاصيل العنوان

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (SUCCESSOR-2)

• Source: A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus

تفاصيل العنوان

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (IKEMA)

• Source: Randomized, Open Label, Multicenter Study Assessing The Clinical Benefit Of Isatuximab Combined With Carfilzomib (Kyprolis®) And Dexamethasone Versus

تفاصيل العنوان

Combination effects of Pistachio hull and carfilzomib on NF-κB p65, MDR1, MRP1, and Caspase3 gene expression in breast cancer cell line

• Authors : Zahra Mirzaei; Sadegh Zarei; Ahmadreza Sayadi

Subjects: Pistachio hull extract; Carfilzomib; Combination therapy

• Source: BMC Complementary Medicine and Therapies, Vol 25, Iss 1, Pp 1-15 (2025)

تفاصيل العنوان

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

• Authors : Janssen Scientific Affairs, LLC

• Source: A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

تفاصيل العنوان

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

• Source: Phase 1 Trial of SX-682, a CXCR 1/2 Inhibitor, in Combination With Standard of Care Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

تفاصيل العنوان

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

• Authors : Karyopharm Therapeutics Inc

• Source: A Phase 2B Study of Selinexor (KPT-330), in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma Relapsing on Current Therapy

تفاصيل العنوان

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (MagnetisMM-20)

• Source: A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH

تفاصيل العنوان

Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

• Authors : Amgen; Celgene; Janssen, LP

• Source: LCI-HEM-MYE-KRdD-001: Phase II Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

تفاصيل العنوان